 Nichole Carlson
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bayes Theorem | 6 | 2020 | 344 | 1.400 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 173 | 1.190 |
Why?
| | Models, Statistical | 6 | 2020 | 636 | 1.090 |
Why?
| | Hydrocortisone | 6 | 2015 | 273 | 1.020 |
Why?
| | Hormones | 3 | 2017 | 135 | 0.920 |
Why?
| | Emphysema | 1 | 2023 | 123 | 0.850 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 195 | 0.800 |
Why?
| | Outpatients | 6 | 2023 | 325 | 0.770 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 336 | 0.740 |
Why?
| | Diabetes Complications | 1 | 2022 | 218 | 0.730 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 327 | 0.720 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2019 | 56 | 0.680 |
Why?
| | Metadata | 1 | 2018 | 19 | 0.670 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 164 | 0.660 |
Why?
| | State Health Plans | 2 | 2008 | 31 | 0.630 |
Why?
| | Computer Simulation | 4 | 2017 | 922 | 0.630 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 216 | 0.610 |
Why?
| | Ovary | 3 | 2017 | 205 | 0.600 |
Why?
| | Models, Biological | 3 | 2017 | 1715 | 0.590 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 152 | 0.560 |
Why?
| | Genome | 1 | 2018 | 277 | 0.560 |
Why?
| | Reproduction | 1 | 2017 | 189 | 0.560 |
Why?
| | Residence Characteristics | 6 | 2010 | 299 | 0.560 |
Why?
| | Child Health Services | 2 | 2008 | 177 | 0.530 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2436 | 0.520 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 16 | 0.510 |
Why?
| | Software | 2 | 2019 | 613 | 0.510 |
Why?
| | Biometry | 2 | 2017 | 65 | 0.500 |
Why?
| | Health Services for the Aged | 2 | 2019 | 71 | 0.490 |
Why?
| | Computational Biology | 1 | 2018 | 588 | 0.490 |
Why?
| | Obesity | 12 | 2023 | 2746 | 0.490 |
Why?
| | Brain Injuries | 5 | 2010 | 484 | 0.490 |
Why?
| | Health Services Accessibility | 4 | 2010 | 781 | 0.480 |
Why?
| | Circadian Rhythm | 4 | 2013 | 401 | 0.470 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 26 | 0.470 |
Why?
| | Pulsatile Flow | 1 | 2013 | 54 | 0.460 |
Why?
| | Environment Design | 3 | 2010 | 22 | 0.460 |
Why?
| | Humans | 87 | 2023 | 118972 | 0.450 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 50 | 0.440 |
Why?
| | Specimen Handling | 1 | 2013 | 165 | 0.410 |
Why?
| | Saliva | 1 | 2013 | 188 | 0.410 |
Why?
| | Female | 67 | 2023 | 61564 | 0.410 |
Why?
| | Walking | 4 | 2010 | 415 | 0.400 |
Why?
| | Gonadotropins | 3 | 2023 | 37 | 0.400 |
Why?
| | Adult | 47 | 2023 | 31512 | 0.390 |
Why?
| | Parkinson Disease | 4 | 2009 | 334 | 0.390 |
Why?
| | Alzheimer Disease | 4 | 2023 | 513 | 0.390 |
Why?
| | White Matter | 2 | 2023 | 115 | 0.370 |
Why?
| | Levodopa | 2 | 2007 | 23 | 0.370 |
Why?
| | Hypogonadism | 2 | 2015 | 77 | 0.370 |
Why?
| | Activities of Daily Living | 3 | 2010 | 354 | 0.360 |
Why?
| | Oregon | 8 | 2011 | 69 | 0.360 |
Why?
| | Aged | 24 | 2023 | 19657 | 0.360 |
Why?
| | Endocrine System | 1 | 2009 | 22 | 0.350 |
Why?
| | Testosterone | 2 | 2010 | 351 | 0.340 |
Why?
| | Estradiol | 6 | 2023 | 476 | 0.320 |
Why?
| | Technology | 1 | 2009 | 83 | 0.320 |
Why?
| | Prenatal Care | 1 | 2010 | 252 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2174 | 0.320 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 48 | 0.310 |
Why?
| | Levonorgestrel | 4 | 2011 | 32 | 0.310 |
Why?
| | Metrorrhagia | 3 | 2011 | 5 | 0.310 |
Why?
| | Health Behavior | 3 | 2010 | 720 | 0.300 |
Why?
| | Perception | 2 | 2007 | 314 | 0.300 |
Why?
| | Cognition Disorders | 3 | 2008 | 529 | 0.300 |
Why?
| | Young Adult | 14 | 2022 | 10793 | 0.300 |
Why?
| | Methylphenidate | 1 | 2007 | 36 | 0.300 |
Why?
| | Smoking Cessation | 1 | 2010 | 360 | 0.290 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 53 | 0.290 |
Why?
| | Male | 39 | 2022 | 57801 | 0.290 |
Why?
| | Middle Aged | 32 | 2021 | 27617 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2021 | 6561 | 0.280 |
Why?
| | Antibodies, Viral | 4 | 2023 | 542 | 0.270 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2513 | 0.270 |
Why?
| | Time Factors | 13 | 2017 | 6412 | 0.270 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3360 | 0.270 |
Why?
| | Poverty | 2 | 2010 | 444 | 0.260 |
Why?
| | Healthcare Disparities | 1 | 2010 | 496 | 0.260 |
Why?
| | Cluster Analysis | 2 | 2023 | 481 | 0.250 |
Why?
| | Gliosis | 2 | 2023 | 35 | 0.250 |
Why?
| | Lung | 3 | 2023 | 3664 | 0.240 |
Why?
| | Medicaid | 1 | 2008 | 411 | 0.240 |
Why?
| | Body Mass Index | 6 | 2019 | 2092 | 0.230 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1129 | 0.220 |
Why?
| | Oocytes | 2 | 2020 | 190 | 0.220 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 4552 | 0.210 |
Why?
| | Prospective Studies | 9 | 2023 | 6471 | 0.210 |
Why?
| | Aging | 4 | 2008 | 1670 | 0.210 |
Why?
| | Hospitalization | 6 | 2022 | 1785 | 0.210 |
Why?
| | Benchmarking | 1 | 2023 | 172 | 0.210 |
Why?
| | Markov Chains | 3 | 2017 | 118 | 0.210 |
Why?
| | Monte Carlo Method | 3 | 2017 | 146 | 0.210 |
Why?
| | Disability Evaluation | 4 | 2018 | 280 | 0.200 |
Why?
| | Healthy Aging | 1 | 2021 | 18 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 73 | 0.200 |
Why?
| | Weight Gain | 2 | 2022 | 493 | 0.190 |
Why?
| | Doxycycline | 2 | 2011 | 60 | 0.190 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 87 | 0.190 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 17 | 0.190 |
Why?
| | Oocyte Donation | 1 | 2020 | 5 | 0.190 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 4 | 0.190 |
Why?
| | Memory, Episodic | 1 | 2021 | 42 | 0.190 |
Why?
| | Prescription Drugs | 1 | 2022 | 113 | 0.190 |
Why?
| | Sarcoidosis | 1 | 2022 | 130 | 0.190 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 33 | 0.190 |
Why?
| | Apomorphine | 3 | 2009 | 4 | 0.180 |
Why?
| | Menstruation | 2 | 1991 | 36 | 0.180 |
Why?
| | Fractals | 1 | 2019 | 6 | 0.180 |
Why?
| | Quality of Life | 5 | 2018 | 2366 | 0.180 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 52 | 0.180 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 20 | 0.180 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 187 | 0.180 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.180 |
Why?
| | Human Growth Hormone | 2 | 2014 | 37 | 0.180 |
Why?
| | Internet | 2 | 2018 | 633 | 0.180 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 30 | 0.180 |
Why?
| | Astrocytes | 1 | 2021 | 177 | 0.170 |
Why?
| | Health Status | 3 | 2010 | 726 | 0.170 |
Why?
| | Spirometry | 1 | 2019 | 263 | 0.170 |
Why?
| | Vital Capacity | 1 | 2019 | 260 | 0.170 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1125 | 0.170 |
Why?
| | Hip Fractures | 1 | 2019 | 79 | 0.160 |
Why?
| | Datasets as Topic | 1 | 2018 | 103 | 0.160 |
Why?
| | Bibliometrics | 1 | 2018 | 51 | 0.160 |
Why?
| | Contraception | 2 | 1991 | 118 | 0.160 |
Why?
| | Sheep, Domestic | 1 | 2017 | 32 | 0.160 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.160 |
Why?
| | Risk Factors | 9 | 2022 | 9000 | 0.160 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 526 | 0.160 |
Why?
| | Eligibility Determination | 2 | 2008 | 55 | 0.150 |
Why?
| | Rhinitis | 2 | 2010 | 129 | 0.150 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.150 |
Why?
| | Algorithms | 3 | 2017 | 1541 | 0.150 |
Why?
| | Pregnancy | 8 | 2023 | 5690 | 0.150 |
Why?
| | Premature Birth | 1 | 2020 | 284 | 0.150 |
Why?
| | Affect | 3 | 2008 | 240 | 0.150 |
Why?
| | Psychomotor Performance | 3 | 2009 | 290 | 0.150 |
Why?
| | Medically Uninsured | 2 | 2008 | 125 | 0.150 |
Why?
| | Lactation | 1 | 2018 | 160 | 0.150 |
Why?
| | Family Planning Services | 2 | 2008 | 68 | 0.150 |
Why?
| | Metabolic Diseases | 1 | 2018 | 103 | 0.150 |
Why?
| | Double-Blind Method | 7 | 2011 | 1687 | 0.150 |
Why?
| | Sinusitis | 2 | 2010 | 175 | 0.150 |
Why?
| | Hypothyroidism | 2 | 2007 | 68 | 0.150 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 98 | 0.140 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 228 | 0.140 |
Why?
| | Adolescent | 13 | 2020 | 18480 | 0.140 |
Why?
| | Endoscopy | 2 | 2010 | 272 | 0.140 |
Why?
| | Cohort Studies | 5 | 2010 | 5116 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2017 | 2874 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2018 | 313 | 0.140 |
Why?
| | Low Back Pain | 1 | 2018 | 100 | 0.140 |
Why?
| | Retrospective Studies | 10 | 2023 | 12978 | 0.140 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 157 | 0.140 |
Why?
| | Antibodies | 1 | 2018 | 392 | 0.140 |
Why?
| | Models, Animal | 1 | 2017 | 363 | 0.140 |
Why?
| | Dietary Fats | 1 | 2018 | 322 | 0.140 |
Why?
| | Personnel Selection | 1 | 2016 | 71 | 0.140 |
Why?
| | Cross-Over Studies | 5 | 2009 | 456 | 0.130 |
Why?
| | Recovery of Function | 2 | 2010 | 604 | 0.130 |
Why?
| | Brain | 5 | 2023 | 2490 | 0.130 |
Why?
| | Otolaryngology | 1 | 2016 | 84 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2015 | 66 | 0.130 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 183 | 0.130 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 107 | 0.130 |
Why?
| | Menstrual Cycle | 3 | 2011 | 113 | 0.130 |
Why?
| | Breast Feeding | 1 | 2018 | 386 | 0.130 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.130 |
Why?
| | Acromegaly | 1 | 2014 | 15 | 0.130 |
Why?
| | Dementia | 2 | 2008 | 208 | 0.120 |
Why?
| | Biomarkers | 4 | 2021 | 3588 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 125 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 178 | 0.120 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 159 | 0.120 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 193 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2017 | 310 | 0.120 |
Why?
| | Analysis of Variance | 5 | 2009 | 1293 | 0.120 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 736 | 0.120 |
Why?
| | Antibody Formation | 2 | 2022 | 276 | 0.120 |
Why?
| | Health Care Costs | 1 | 2017 | 394 | 0.120 |
Why?
| | Interviews as Topic | 3 | 2010 | 599 | 0.120 |
Why?
| | Secretory Rate | 1 | 2013 | 16 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 989 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 277 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 164 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 195 | 0.110 |
Why?
| | Electronics | 1 | 2013 | 76 | 0.110 |
Why?
| | Adenoma | 1 | 2014 | 191 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 399 | 0.110 |
Why?
| | Medical Records | 1 | 2013 | 163 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2022 | 2674 | 0.110 |
Why?
| | Age Factors | 8 | 2018 | 2995 | 0.110 |
Why?
| | Wakefulness | 1 | 2013 | 128 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 468 | 0.100 |
Why?
| | Urban Health | 2 | 2009 | 78 | 0.100 |
Why?
| | Antibodies, Monoclonal | 3 | 2022 | 1284 | 0.100 |
Why?
| | Insulin | 1 | 2022 | 2162 | 0.100 |
Why?
| | Memory | 3 | 2008 | 230 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2015 | 467 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4596 | 0.100 |
Why?
| | Cognition | 3 | 2008 | 1024 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 374 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2009 | 307 | 0.100 |
Why?
| | Progestins | 1 | 2011 | 77 | 0.100 |
Why?
| | Amenorrhea | 1 | 2011 | 28 | 0.100 |
Why?
| | Dopamine Agonists | 2 | 2008 | 30 | 0.100 |
Why?
| | Equipment Design | 1 | 2013 | 519 | 0.100 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 23 | 0.100 |
Why?
| | Risk Assessment | 2 | 2017 | 3057 | 0.100 |
Why?
| | Birth Certificates | 1 | 2010 | 8 | 0.100 |
Why?
| | Estrone | 1 | 2010 | 36 | 0.100 |
Why?
| | Birth Rate | 2 | 2020 | 20 | 0.100 |
Why?
| | Automobile Driving | 2 | 2010 | 128 | 0.100 |
Why?
| | Cytokines | 2 | 2015 | 1900 | 0.100 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 39 | 0.100 |
Why?
| | Live Birth | 2 | 2020 | 47 | 0.100 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 11 | 0.090 |
Why?
| | Diet | 1 | 2018 | 1153 | 0.090 |
Why?
| | Pregnancy Rate | 2 | 2020 | 55 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2017 | 968 | 0.090 |
Why?
| | Geographic Information Systems | 2 | 2010 | 40 | 0.090 |
Why?
| | United States | 6 | 2020 | 12555 | 0.090 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 73 | 0.090 |
Why?
| | Thyroxine | 2 | 2007 | 63 | 0.090 |
Why?
| | Cities | 1 | 2010 | 96 | 0.090 |
Why?
| | Abortion, Induced | 2 | 2008 | 73 | 0.090 |
Why?
| | Sex Factors | 5 | 2018 | 1781 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1810 | 0.090 |
Why?
| | Personality | 1 | 2011 | 115 | 0.090 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 8 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2015 | 9342 | 0.090 |
Why?
| | Exercise | 3 | 2010 | 1657 | 0.090 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 34 | 0.090 |
Why?
| | Independent Living | 1 | 2010 | 86 | 0.080 |
Why?
| | Telecommunications | 1 | 2009 | 17 | 0.080 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 76 | 0.080 |
Why?
| | Mortality | 1 | 2011 | 299 | 0.080 |
Why?
| | Child, Preschool | 4 | 2018 | 9491 | 0.080 |
Why?
| | Progesterone | 3 | 2015 | 242 | 0.080 |
Why?
| | Postmenopause | 1 | 2010 | 305 | 0.080 |
Why?
| | Rural Health | 1 | 2009 | 72 | 0.080 |
Why?
| | Drug Interactions | 2 | 2007 | 352 | 0.080 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.080 |
Why?
| | Foot | 1 | 2009 | 106 | 0.080 |
Why?
| | Logistic Models | 2 | 2010 | 1901 | 0.080 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 84 | 0.080 |
Why?
| | Life Change Events | 1 | 2009 | 134 | 0.080 |
Why?
| | Vaccinia | 1 | 2007 | 19 | 0.080 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.080 |
Why?
| | Vaccinia virus | 1 | 2007 | 34 | 0.080 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 23 | 0.080 |
Why?
| | Ointments | 1 | 2007 | 25 | 0.080 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 32 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2490 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 267 | 0.080 |
Why?
| | Counseling | 1 | 2010 | 353 | 0.080 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 29 | 0.080 |
Why?
| | Population Surveillance | 1 | 2010 | 413 | 0.080 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 11 | 0.080 |
Why?
| | Atrophy | 1 | 2007 | 164 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 116 | 0.070 |
Why?
| | Time Perception | 1 | 2007 | 23 | 0.070 |
Why?
| | Awareness | 1 | 2007 | 93 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 126 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2007 | 181 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 100 | 0.070 |
Why?
| | Movement | 1 | 2009 | 248 | 0.070 |
Why?
| | Tremor | 1 | 2007 | 46 | 0.070 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 176 | 0.070 |
Why?
| | Suicide, Attempted | 1 | 2009 | 316 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 1001 | 0.070 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 108 | 0.070 |
Why?
| | Infant | 3 | 2010 | 8293 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1864 | 0.070 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 554 | 0.070 |
Why?
| | Paroxetine | 1 | 2005 | 7 | 0.070 |
Why?
| | Treatment Failure | 2 | 2022 | 341 | 0.070 |
Why?
| | Animals | 6 | 2023 | 33381 | 0.070 |
Why?
| | Health Policy | 1 | 2008 | 333 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 410 | 0.060 |
Why?
| | Administration, Oral | 1 | 2007 | 756 | 0.060 |
Why?
| | Neurologic Examination | 2 | 2008 | 126 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1795 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2008 | 437 | 0.060 |
Why?
| | Health Promotion | 1 | 2010 | 691 | 0.060 |
Why?
| | Child | 5 | 2018 | 19129 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 537 | 0.060 |
Why?
| | Family | 1 | 2008 | 585 | 0.060 |
Why?
| | Likelihood Functions | 2 | 2017 | 136 | 0.060 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 11 | 0.060 |
Why?
| | Neurites | 1 | 2023 | 45 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 73 | 0.060 |
Why?
| | Linear Models | 2 | 2020 | 827 | 0.060 |
Why?
| | Sex Characteristics | 1 | 2007 | 671 | 0.060 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 90 | 0.060 |
Why?
| | Emotions | 1 | 2007 | 495 | 0.060 |
Why?
| | Physical Fitness | 1 | 2004 | 179 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 660 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 770 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 4 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 70 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 380 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 12 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1200 | 0.050 |
Why?
| | Acids | 1 | 2002 | 20 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3174 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 119 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1510 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 243 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 996 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 61 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 687 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 126 | 0.050 |
Why?
| | Neuroimaging | 1 | 2023 | 256 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 89 | 0.050 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 156 | 0.050 |
Why?
| | Puberty | 1 | 2002 | 144 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2022 | 174 | 0.050 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.050 |
Why?
| | Breast Neoplasms | 2 | 2011 | 1965 | 0.050 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 19 | 0.050 |
Why?
| | Leptin | 1 | 2002 | 231 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2022 | 253 | 0.050 |
Why?
| | Fasting | 1 | 2002 | 264 | 0.050 |
Why?
| | Embryo Transfer | 1 | 2020 | 28 | 0.050 |
Why?
| | Blastocyst | 1 | 2020 | 44 | 0.050 |
Why?
| | Prostaglandins | 1 | 2000 | 78 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 124 | 0.040 |
Why?
| | Case-Control Studies | 4 | 2009 | 3171 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1132 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 1945 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1185 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 234 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 97 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1868 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 85 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 303 | 0.040 |
Why?
| | Denmark | 1 | 2017 | 41 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 788 | 0.040 |
Why?
| | Electromyography | 1 | 1999 | 326 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 389 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2000 | 333 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 16 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2424 | 0.040 |
Why?
| | Milk | 1 | 2018 | 125 | 0.040 |
Why?
| | Psychological Tests | 1 | 2018 | 129 | 0.040 |
Why?
| | Confidence Intervals | 2 | 2008 | 324 | 0.040 |
Why?
| | Viruses | 1 | 2018 | 96 | 0.040 |
Why?
| | Biostatistics | 1 | 2017 | 18 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2023 | 654 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 59 | 0.040 |
Why?
| | Thyrotropin | 2 | 2007 | 105 | 0.040 |
Why?
| | Neoplasms | 1 | 2011 | 2179 | 0.040 |
Why?
| | Health Surveys | 2 | 2009 | 454 | 0.040 |
Why?
| | Drug Combinations | 2 | 2011 | 291 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 870 | 0.040 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 827 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 758 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 187 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 56 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 253 | 0.030 |
Why?
| | Systole | 1 | 2015 | 168 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1384 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 39 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 229 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 110 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1171 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 794 | 0.030 |
Why?
| | Risk | 1 | 2017 | 853 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 631 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 80 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 525 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 4908 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 208 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3730 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 166 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 606 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3003 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 649 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 379 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4196 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 842 | 0.030 |
Why?
| | Follicular Phase | 2 | 2004 | 41 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 328 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2008 | 1032 | 0.030 |
Why?
| | Fatty Acids | 1 | 2015 | 407 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 601 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 468 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 682 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 299 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1474 | 0.030 |
Why?
| | Prognosis | 1 | 1999 | 3443 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 829 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 21 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 49 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 52 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5255 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 127 | 0.020 |
Why?
| | Amides | 1 | 2010 | 86 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 485 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 671 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 150 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 984 | 0.020 |
Why?
| | Income | 1 | 2010 | 173 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 774 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 84 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 355 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 162 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 156 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 10 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 21 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 30 | 0.020 |
Why?
| | Employment | 1 | 2010 | 135 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 35 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 11 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 764 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 13 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 269 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 421 | 0.020 |
Why?
| | Parity | 1 | 1988 | 101 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 64 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 184 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 7 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 188 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 56 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 20 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 25 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 28 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 4708 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 41 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 380 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 147 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 136 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 86 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 437 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 59 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 462 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 146 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 43 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 46 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 90 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 204 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 55 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 438 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 84 | 0.020 |
Why?
| | Research | 1 | 2010 | 411 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 86 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 160 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 467 | 0.020 |
Why?
| | Safety | 1 | 2008 | 304 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 85 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 610 | 0.020 |
Why?
| | Mental Recall | 1 | 2007 | 180 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 499 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 301 | 0.020 |
Why?
| | Dopamine Agents | 1 | 2005 | 14 | 0.020 |
Why?
| | Virus Diseases | 1 | 2007 | 198 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 388 | 0.020 |
Why?
| | Vestibular Diseases | 1 | 2005 | 22 | 0.020 |
Why?
| | Dizziness | 1 | 2005 | 70 | 0.020 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 58 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 627 | 0.020 |
Why?
| | Length of Stay | 1 | 2009 | 1032 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1527 | 0.020 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 40 | 0.020 |
Why?
| | Self Efficacy | 1 | 2008 | 366 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2007 | 233 | 0.020 |
Why?
| | Diet Records | 1 | 2004 | 81 | 0.020 |
Why?
| | Research Design | 1 | 2010 | 969 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 51 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1636 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 502 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 709 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 309 | 0.010 |
Why?
| | Skin | 1 | 2007 | 657 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 154 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 972 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1244 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 249 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 1969 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 27 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 8 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 34 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 24 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 41 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 51 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 185 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 91 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 96 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 586 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 447 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 163 | 0.010 |
Why?
| | Periodicity | 1 | 2000 | 56 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2459 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 44 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 296 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 345 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 23 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 469 | 0.010 |
Why?
| | Vaccination | 1 | 2007 | 1222 | 0.010 |
Why?
| | Fever | 1 | 2000 | 283 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2275 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1203 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 660 | 0.010 |
Why?
| | Mice | 1 | 2007 | 15520 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|